ADIPOQ and atherosclerosis: In EAT from CAD patients, adiponectin levels are reduced at the same time that the production of IL-6, TNFα, and TLR-4 is increased, while adiponectin treatment has been proved to prevent atherosclerosis by reducing TNFα production in macrophages and ROS production by endothelial cells, as well as by increasing endothelial cell migration and vascularization [196,212,221].